|Mr. Paul Baehr||Chairman, Chief Exec. Officer and Pres||199.65k||N/A||74|
|Mr. Richard Collin CPA-CA||Director of Fin. and Sec.||140.03k||N/A||N/A|
|Mr. Claire Bergeron||VP of Admin.||N/A||N/A||N/A|
|Ms. Catherine Poulin||VP of Manufacturing||N/A||N/A||N/A|
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. The company produces a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B. It also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, the company provides lyophilization services related to the making of components for disposable medical devices, which are used in the hemostasis point of care market. IBEX Technologies Inc. offers its enzymes to manufacturers of medical devices, quality control labs, and academic research institutions. The company is based in Montreal, Canada.
IBEX Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.